Literature DB >> 84150

Arginine therapy of argininosuccinase deficiency.

S W Brusilow, M L Batshaw.   

Abstract

Argininosuccinic acid (A.S.A.) contains the two waste nitrogen atoms later excreted in urea in healthy people, and it has a renal clearance similar to the glomerular filtration-rate. Therefore, argininosuccinic acid might provide a vehicle for the excretion of waste nigrogen in patients with argininosuccinase deficiency, providing that stoichiometric amounts of ornithine are available. When two infants with no, or very little, erythrocyte argininosuccinase activity who were in neonatal hyperammonaemic coma were treated with supplementary arginine (4-5 mmol/kg/day) plasma ammonium, glutamine, and alanine concentrations became normal. One infant grew and developed normally during the first month of life on a protein intake of 2 g/kg/day. The other infant had sustained lathal brain damage before arginine therapy was tried and she died aged 17 days. Arginine supplementation may be effective therapy for argininosuccinase deficiency because it promotes A.S.A. synthesis and hence excretion of waste nitrogen. The effects of high plasma-A.S.A. concentrations are unknown.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 84150     DOI: 10.1016/s0140-6736(79)90518-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Creatine metabolism in urea cycle defects.

Authors:  Sara Boenzi; Anna Pastore; Diego Martinelli; Bianca Maria Goffredo; Arianna Boiani; Cristiano Rizzo; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2012-05-30       Impact factor: 4.982

2.  Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders.

Authors:  Roland Posset; Angeles Garcia-Cazorla; Vassili Valayannopoulos; Elisa Leão Teles; Carlo Dionisi-Vici; Anaïs Brassier; Alberto B Burlina; Peter Burgard; Elisenda Cortès-Saladelafont; Dries Dobbelaere; Maria L Couce; Jolanta Sykut-Cegielska; Johannes Häberle; Allan M Lund; Anupam Chakrapani; Manuel Schiff; John H Walter; Jiri Zeman; Roshni Vara; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

3.  Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation.

Authors:  Claude Bachmann
Journal:  Eur J Pediatr       Date:  2003-03-27       Impact factor: 3.183

4.  Argininosuccinic aciduria: long-term treatment with arginine.

Authors:  H G Parsons; R B Scott; A Pinto; R J Carter; F F Snyder
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

Review 5.  Alternative pathway therapy for urea cycle disorders.

Authors:  F Feillet; J V Leonard
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

6.  Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects.

Authors:  M A Sapienza; S A Kharitonov; I Horvath; K F Chung; P J Barnes
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

7.  Menstrual cycle and gonadal steroid effects on symptomatic hyperammonaemia of urea-cycle-based and idiopathic aetiologies.

Authors:  W W Grody; R J Chang; N M Panagiotis; D Matz; S D Cederbaum
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 8.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.